Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
GSK plc's quarterly P/E stands at 40.9x, down 3.3% year-over-year. EV/EBITDA has expanded 31.7% YoY to 24.8x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 16.16 | 40.87 | 11.15 | 13.71 | 12.42 | 42.27 | — | 17.19 | 21.43 | 54.50 | 12.59 | 11.14 | 12.35 |
| — | -3.3% | — | -20.2% | -42.1% | -22.4% | — | +54.3% | +73.5% | +359.1% | -35.0% | -57.0% | -0.2% | |
| P/S Ratio | 2.76 | 3.17 | 2.62 | 2.47 | 2.67 | 2.16 | 2.60 | 2.52 | 2.99 | 2.37 | 2.29 | 2.54 | 2.61 |
| — | +46.8% | +0.7% | -1.8% | -11.0% | -8.9% | +13.8% | -1.0% | +14.5% | -2.8% | +19.1% | -20.4% | -15.1% | |
| P/B Ratio | 5.68 | 6.29 | 4.23 | 4.01 | 4.55 | 5.36 | 6.20 | 4.56 | 5.28 | 4.68 | 4.84 | 4.72 | 5.20 |
| — | +17.4% | -31.8% | -12.0% | -13.8% | +14.5% | +28.1% | -3.4% | +1.5% | -34.3% | -21.7% | +46.7% | -22.0% | |
| P/FCF | 15.14 | 16.97 | 8.62 | 13.48 | 28.74 | 14.68 | 15.89 | 29.56 | 25.16 | 6.29 | 10.86 | 23.62 | — |
| — | +15.6% | -45.8% | -54.4% | +14.3% | +133.2% | +46.3% | +25.2% | — | -56.6% | -18.9% | +29.1% | — | |
| EV / EBITDA | 9.57 | 24.78 | 8.19 | 7.68 | 8.08 | 18.81 | 21.11 | 10.62 | 13.13 | 19.97 | 9.50 | 9.28 | 8.72 |
| — | +31.7% | -61.2% | -27.6% | -38.5% | -5.8% | +122.2% | +14.4% | +50.6% | +107.0% | +1.0% | -31.0% | -15.0% | |
| EV / EBIT | 14.62 | 29.71 | 10.40 | 11.80 | 10.81 | 29.49 | 109.39 | 14.53 | 17.60 | 44.72 | 12.17 | 11.08 | 11.25 |
| — | +0.8% | -90.5% | -18.8% | -38.6% | -34.1% | +798.5% | +31.2% | +56.5% | +269.8% | -27.0% | -54.6% | -7.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
GSK plc's operating margin was 2.3% in Q4 2025, down 28.1 pp QoQ and down 6.3 pp YoY. The trailing four-quarter average of 21.9% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.5% | 69.5% | 73.6% | 72.9% | 74.2% | 68.5% | 70.1% | 73.1% | 73.2% | 70.0% | 72.1% | 73.1% | 72.0% |
| — | +1.5% | +5.0% | -0.3% | +1.3% | -2.1% | -2.8% | +0.0% | +1.7% | +0.4% | +4.4% | +6.5% | +15.8% | |
| Operating Margin | 21.9% | 2.3% | 30.3% | 25.3% | 29.5% | 8.6% | 2.4% | 20.9% | 20.2% | 7.1% | 23.9% | 29.8% | 30.0% |
| — | -73.5% | +1186.1% | +21.3% | +45.7% | +20.5% | -90.1% | -30.0% | -32.4% | -71.9% | +57.3% | +91.2% | -6.1% | |
| Net Margin | 17.5% | 7.9% | 23.6% | 18.1% | 21.6% | 5.1% | -0.7% | 14.9% | 14.2% | 4.3% | 18.0% | 22.6% | 21.4% |
| — | +55.7% | +3353.5% | +21.4% | +52.1% | +17.3% | -104.0% | -34.2% | -33.7% | -78.1% | -87.0% | +87.1% | -14.5% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 38.5% | 3.4% | 9.8% | 7.7% | 10.6% | 3.1% | -0.4% | 6.9% | 6.3% | 2.2% | 9.5% | 11.0% | 12.4% |
| — | +8.4% | +2720.2% | +12.5% | +66.9% | +41.3% | -104.0% | -37.7% | -48.8% | -85.0% | -83.7% | +168.5% | +44.9% | |
| ROA | 9.3% | 0.9% | 2.5% | 1.8% | 2.4% | 0.7% | -0.1% | 1.6% | 1.4% | 0.5% | 2.0% | 2.2% | 2.2% |
| — | +24.1% | +2887.0% | +13.6% | +68.0% | +50.5% | -104.5% | -27.4% | -37.6% | -79.6% | -84.2% | +145.2% | +16.2% | |
| ROIC | 18.6% | 0.4% | 4.9% | 4.1% | 5.4% | 2.0% | 0.5% | 3.5% | 3.1% | 1.2% | 3.9% | 4.3% | 4.9% |
| — | -80.8% | +963.9% | +17.2% | +70.6% | +67.1% | -88.0% | -18.4% | -36.0% | -75.6% | +66.2% | +117.8% | +31.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
GSK plc's Debt/EBITDA ratio is 15.3x, up from 7.2x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.11 | 1.11 | 1.13 | 1.21 | 1.35 | 1.30 | 1.19 | 1.23 | 1.34 | 1.41 | 1.65 | 1.77 | 1.85 |
| — | -14.4% | -5.6% | -1.7% | +0.5% | -7.8% | -27.7% | -30.3% | -27.3% | -32.3% | -34.9% | +80.8% | -11.1% | |
| Debt / EBITDA | 1.65 | 15.31 | 7.17 | 7.47 | 7.83 | 15.33 | 14.09 | 9.37 | 11.01 | 19.21 | 10.06 | 10.53 | 9.50 |
| — | -0.1% | -49.1% | -20.3% | -28.9% | -20.2% | +40.0% | -11.0% | +15.9% | +111.4% | -12.5% | -21.7% | -6.8% | |
| Current Ratio | 0.82 | 0.82 | 0.84 | 0.87 | 0.87 | 0.78 | 0.81 | 0.82 | 0.87 | 0.88 | 0.95 | 0.88 | 0.95 |
| — | +4.5% | +3.7% | +5.3% | +0.1% | -11.5% | -15.0% | -5.8% | -9.0% | -2.8% | -1.8% | -38.9% | +4.6% | |
| Quick Ratio | 0.54 | 0.54 | 0.55 | 0.57 | 0.58 | 0.52 | 0.53 | 0.54 | 0.58 | 0.62 | 0.70 | 0.63 | 0.69 |
| — | +3.7% | +3.6% | +6.2% | +0.1% | -16.3% | -24.7% | -14.4% | -16.5% | -8.9% | -5.4% | -52.2% | +1.3% | |
| Interest Coverage | 10.23 | 0.97 | 15.53 | 10.99 | 13.68 | 4.83 | 1.21 | 9.46 | 8.98 | 2.08 | 10.71 | 11.57 | 10.26 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonGSK plc's current P/E is 16.2x. The average P/E over the last 4 quarters is 19.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
GSK plc's current operating margin is 21.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking GSK plc's business trajectory between earnings reports.